GSK presented interim results from Part 1 of the RUBY Phase III trial, which evaluated the efficacy of Jemperli (dostarlimab) plus chemotherapy (carboplatin-paclitaxel) followed by Jemperli versus chemotherapy with placebo followed by placebo.
The study recruited adults with primary or advanced endometrial cancer. Jemperli, the chemotherapy combination showed significant and clinically meaningful improvement in progression-free survival (PFS). There was a trend in the improvement of the overall survival in Jemperli's arm.
The safety profile was consistent with the existing safety profile.
Merck has presented the Phase 3 trial data of the NRG‑GY018 trial, demonstrating the efficacy of Keytruda (pembrolizumab) plus chemotherapy in patients with advanced or recurrent endometrial cancer, irrespective of mismatch repair status.
In mismatch repair proficient (pMMR) cancer, the combination has reduced the risk of disease progression or death by 46% versus placebo. The median progression-free survival was 13.1 months versus 8.7 months in the placebo arm.
In patients with mismatch repair deficient (dMMR) cancer, risk of disease progression or death was decreased by 70% versus chemotherapy. The median progression-free survival was not met in the Keytruda arm compared to 7.6 months in patients on chemotherapy alone.
The adverse event profile was similar to the established safety profile.